Skip to main content
. 2016 Jul 13;7(32):52340–52353. doi: 10.18632/oncotarget.10566

Figure 6. Hsa-miR-184 suppresses the AKT2/mTOR pathway, and inhibits cell proliferation and migration.

Figure 6

A. Immunoblotting of p-AKT2, AKT2, p-mTOR, mTOR, p-p70S6K, p70S6K in 30 dpd hiPSC-RPE transfected with NC mimic/hsa-miR-184 mimic. B. Schematic of the hsa-miR-184 regulatory network. C-F. Proliferative rates of ARPE-19 cells transfected with NC mimic (C), hsa-miR-184 mimic (C), NC inhibitor (E), and hsa-miR-184 inhibitor (E), and migration of ARPE-19 cells transfected with NC mimic (D), hsa-miR-184 mimic (D), NC inhibitor (F), and hsa-miR-184 inhibitor (F).